Ocular Clinical Trials

1) Contact Lens Wearers with Demodex Blepharitis and Dry Eye Symptoms

• Age: 18 or older
• Contact lens wearer with demodex blepharitis diagnosis and dry eye symptoms
• Real life observational study, no required study treatment, fill out in-office questionnaires
• 4 short in-person office visits over 6 months
• Total Compensation for all visits: $585, e-gift card emailed after each visit

2) Studies for Contact Lens Wearers with Dry Eye Symptoms

• Age: 18 or older
• Full time daily contact lens wearer with dry eye symptoms
• Use FDA approved Rx dry eye treatment twice/day, before and after contact lens use
• Willing to record daily time for CL application/removal, application of dry eye medication, and artificial tears application
• 3 or 4 in-person office visits over 3 months
• BENEFITS OF STUDY PARTICIPATION: complimentary dry eye treatment for 3 months, potential increase in comfortability regarding contact lens wear, and compensation for your participation
• Total Compensation after completing all visits: $325 or $400

Clinical Research Portfolio & Ophthalmic Site Capabilities

Ocular Clinical Trials partners with global pharmaceutical sponsors and medical device innovators to accelerate market access for next-generation eye care solutions. Led by Founder and Principal Investigator Dr. Bridgitte Shen Lee—a distinguished industry Key Opinion Leader—our premier clinical research site operates alongside Vision Optique, an elite private practice and multi-specialty ocular health hub established in Houston in 1999.

This integrated ecosystem provides a highly compliant framework backed by a large, diverse patient base. With a proven track record of successfully executing 24 FDA-regulated studies (Phases I–IV & IITs) involving 500+ participants, our site delivers an elite investigational infrastructure optimized for rapid enrollment, immaculate regulatory compliance, and pristine data capture.

Core Areas of Clinical Investigation

Contact Lens Studies

We participate in clinical trials to help develop next-generation contact lens technologies and solutions. Investigational tracks include:

• Testing novel lens materials for superior oxygen permeability, hydration, optimal visual performance, and long-term wearer comfort.
• Evaluating specialty lens designs for astigmatism, presbyopia, and myopia management.
• Studying the biochemical effects of advanced lens care systems on ocular surface health.
• Developing smart contact lenses engineered with integrated, built-in drug delivery architectures.

Ophthalmic Pharmaceutical Research

Our research team actively partners with leading global eye care companies to study and develop targeted therapies designed to diagnose, treat, or prevent complex diseases of the eye. Our pipeline focus includes:

• Formulating specialized pharmaceutical agents suitable for targeted topical ocular delivery, including advanced eye drops, ointments, and innovative nasal sprays.
• Evaluating the clinical endpoints, safety, and efficacy of novel ocular drugs through rigorous, FDA-regulated protocols.
• Investigating pioneering therapies for presbyopia management alongside advanced dry eye disease, Demodex blepharitis, ocular rosacea, and severe allergic conjunctivitis.

Myopia Management

Ocular Clinical Trials (OCT) possesses a robust history of executing innovative clinical protocols to manage and slow the progression of myopia (nearsightedness), particularly in children and adolescents. High myopia exponentially increases the risk for sight-threatening eye conditions later in life, such as retinal detachment, glaucoma, cataracts, and myopic maculopathy.

Leveraging our proven background in conducting both specialized ophthalmic lens and contact lens myopia management studies, our clinical trials evaluate the longitudinal efficacy and safety of advanced treatment interventions:

• Deploying specialty myopia control spectacle lenses and daytime soft contact lenses.
• Evaluating advanced nighttime Orthokeratology (Ortho-K) lens materials.
• Optimizing low-dose atropine eye drop therapeutic regimens.

Diagnostic AI Technology & Equipment

Our site accelerates the clinical integration of AI-powered diagnostic systems and next-generation ophthalmic imaging platforms. Leveraging our tech-forward investigational infrastructure, our pipeline focus includes:

• Testing and validating intelligent algorithms that enable earlier detection, highly accurate mapping, and precise monitoring of progressive ocular diseases.
• Evaluating advanced imaging hardware and machine learning applications for seamless clinical workflow deployment and baseline screening accuracy.
• Conducting data-rich device validation studies backed by our extensive, well-documented multi-specialty patient database.

High-Compliance Ophthalmic Clinical Trial Site | Houston, TX

Ocular Clinical Trials is spearheaded by Dr. Bridgitte Shen Lee, a distinguished industry Key Opinion Leader who leverages her extensive clinical expertise to lead our premier research institution. Our organization provides global pharmaceutical and medical device sponsors with an elite framework of clinical excellence, characterized by an unmatched ability to achieve rapid participant enrollment while maintaining exceptional data integrity and strict protocol execution. Our elite research team has successfully executed 24 FDA-regulated clinical studies and Investigator-Initiated Trials (IITs) involving over 500 participants since 2020.

Site Performance Metrics

Metric                                              Target / Capability

Active Patient Database            30,000+ Multi-Specialty Patients

Feasibility Response Time         Within 48 Business Hours

Investigational Framework      Phase I–IV & Investigator-Initiated Trials (IITs)

Regulatory Compliance            100% GCP / CITI Certified Staff

 Therapeutic Areas & Core Expertise

• Anterior Segment & Dry Eye: Advanced diagnostic tracking of Meibomian Gland Dysfunction (MGD), ocular surface and peri-orbital skin conditions, and targeted therapeutic endpoints.
• Contact Lens Innovation: High-volume evaluation protocols for daily disposables, multifocals, toric designs, and custom specialized lens materials.
• Myopia Management: Longitudinal pediatric studies evaluating advanced spectacle lenses, daytime contact lenses, and Ortho-K modalities.
• Digital Eye Health: Specialized evaluation frameworks tailored specifically around modern digital lifestyle and screen-related eye health issues.

Diagnostic Infrastructure & Facility Assets

• Advanced Ocular Surface Imaging: Equipped with the LipiView, LipiFlow, Firefly, and Canon slit lamp camera platforms to deliver precise, non-invasive tear film analysis and high-definition meibomian gland imaging. 
• Dedicated Research Lanes: Tightly controlled clinical examination setups reserved exclusively for clinical trial subjects to ensure absolute protocol compliance. Features two specialized 4-meter visual acuity lanes meeting strict light luminance requirements.
• Secure Investigational Product (IP) Storage: Climate-controlled, restricted-access storage rooms and high-security lockers are fully compliant with strict chain-of-custody tracking protocols.
• Real-Time Remote Monitoring Hub: High-speed fiber internet and dedicated physical workstations optimized for seamless, secure remote auditing by CRAs and monitors.
• Executive Conference Facilities: A dedicated, well-equipped conference room with high-speed fiber internet access reserved exclusively for monitors and clinical research auditors.

Principal Investigator Profile

Dr. Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO

As a triple-fellowship optometrist and international Key Opinion Leader, Dr. Shen Lee brings over 25 years of clinical mastery and bilingual (English/Chinese) leadership to global clinical protocols. Backed by full-time, certified sub-investigators and dedicated Clinical Research Coordinators, our Houston site minimizes execution friction for global, cross-border sponsors.

Certifications: ✓ CITI Trained | ✓ Good Clinical Practice (GCP) Compliant | ✓ IATA Certified (Dangerous Goods Shipping)

Local Advantage

Based in Houston, Texas, our site has access to one of the nation’s largest and most ethnically diverse metropolitan patient populations, enabling representative recruitment. Our proximity to the Texas Medical Center—the world’s largest medical complex—also provides strong regional advantages for clinical coordination.

Corporate Collaborations & Pipeline Inquiries

We are actively seeking new study opportunities to expand our investigational pipeline. We welcome protocol collaborations, beta-site partnerships, clinical trial pipeline inquiries, and protocol valuations with industry innovators to translate advanced ophthalmic science directly into validated commercial therapies.

To discuss upcoming clinical trials or corporate advisory boards, please contact our research team directly:

• Call: (713) 838-2020, option 5
• Email: [email protected]